Published in Mental Health Business Week, July 23rd, 2005
In a "multicenter, randomized, double-blind, placebo-controlled, crossover trial," J.J. Theal and colleagues at Toronto Western Hospital "evaluated the efficacy of ondansetron, a selective 5-HT3 receptor subtype antagonist, for treating fatigue in PBC."
"A crossover design was chosen, allowing subjects to serve as their own...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.